The Latest Analyst Ratings For 4D Molecular Therapeutics
Portfolio Pulse from Benzinga Insights
4D Molecular Therapeutics (NASDAQ:FDMT) has been analyzed by five analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $38.8, a decrease from the previous $43.40. The company faces financial challenges, including a significant revenue decline and negative net margin, but has a strong ROE and ROA. Analysts maintain varied ratings, with some lowering their price targets.
September 09, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
4D Molecular Therapeutics has received mixed analyst ratings, with a decrease in the average price target to $38.8. The company faces financial challenges, including a significant revenue decline and negative net margin, but shows strong ROE and ROA.
The mixed analyst ratings and lowered price target suggest a neutral short-term impact on FDMT's stock price. While financial challenges are evident, the company's strong ROE and ROA provide some positive outlook. The decrease in the average price target indicates a cautious stance by analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100